A Phase II, Open Label, Multi-center, Multi-arm Study of Ceritinib in Patients With Advanced Solid Tumors and Hematological Malignancies Characterized by Genetic Abnormalities of Anaplastic Lymphoma Kinase (ALK)
Phase of Trial: Phase II
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Ceritinib (Primary)
- Indications Solid tumours
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis; Novartis Pharma A.G.
- 19 Mar 2018 This trial has been completed in France.
- 16 Mar 2018 Planned End Date changed from 11 Mar 2019 to 30 Apr 2018.
- 03 Jan 2018 This trial has been completed in Germany, according to European Clinical Trials Database.